OncoKDM™ interpretation platform used in routine laboratory practice at ETZ (Elisabeth TweeSteden Hospital Pathologie Zuid-West Nederland) Tilburg, Netherlands

OncoKDM™ interpretation platform used in routine laboratory practice at ETZ (Elisabeth TweeSteden Hospital Pathologie Zuid-West Nederland) Tilburg, Netherlands

The ETZ (Elisabeth-TweeSteden Hospital) is a leading hospital offering multiple clinical specialties including oncology and trauma across three locations for the population of the Central Brabant (NL) region and beyond. High quality care for patients is central to every decision made with continual investment in seeking and working with partners who can introduce innovation to clinical care and improve productivity.

The pathology laboratory was already using solid tumor panel for variant interpretation alongside a BioIT reporting tool. Yet, there was a clear need for a solution that could streamline the workflow returning results faster to Oncologists so they could signpost their patients to innovative treatment plans. Following the introduction of the OncoKDMTM interpretation platform by ETZ in July 2022 and the seamless integration of OncoDNA’s expertise into their laboratory, significant reductions in turnaround times for solid tumor analysis have been achieved.

“ Since July 2022, ETZ analyises more than 50 patient samples a month using the OncoKDMTM platform and has significantly benefited from OncoDNA’s support during the implementation process. “

Dr. Jaco Verweij | Medical Molecular Microbiologist

About OncoKDM

OncoKDMTM relies on OncoKDOTM, OncoDNA’s proprietary database proprietary database counting no less than 4,500,000 genetic variants, 1,400 cancer drugs, and data from 9,000 clinical trials. Operating after the biological interpretation (secondary analysis), OncoKDMTM tool facilitates the clinical interpretation (tertiary analysis).

About OncoDNA

Founded in 2012 with the vision of providing precision medicine in Oncology to multiple markets around the world, primarily focused on the patient. In a short space of time, we have made a significant contribution to the adoption of precision oncology as a result of providing a relevant solution to a wide range of customers, the core of which is our constantly updated database (KDO).

Our scientific teams continuously scan the literature for new information in Oncology so we can develop tests that guide oncological treatments. Once we identify relevant biomarkers, we create accompanying tests (OncoDEEP®, OncoSELECT®, OncoFOLLOW). to detect and report on these biomarkers. The resulting reports are then shared through our user-friendly web-based platform (OncoKDMTM).

OncoDNA is headquartered in Belgium, and its entities – Biosequence and IntegraGen – are based in Spain, France and the United States. The Group employs over 100 employees across 9 countries, works with an international network of 35 distributors and collaborates with both European-based and US-based subcontracted accredited laboratories.

We are keen to meet laboratory partners and oncologists who would like to benefit from our expertise and work in partnership with us for the benefit of oncologists and their patients. For further information, visit www.oncodna.com and connect with us on LinkedIn, Facebook or Twitter.

You may also be interested in these resources

Press Release

OncoDNA laboratory has received the CAP accreditation

Gosselies, January 4th – The Certificate of Accreditation has been issued to the IntegraGen laboratory by The College of American Pathologists (CAP) for having successfully met the Laboratory Accreditation Program Standards. “The CAP accreditation is a critical step for OncoDNA, and we...

Share This